Skip to main content
Erschienen in: Current Treatment Options in Psychiatry 2/2015

01.06.2015 | Substance Use Disorders (FG Moeller, Section Editor)

Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic

verfasst von: Xiaofan Li, M.D., Ph.D., Daryl Shorter, M.D., Thomas Kosten, M.D.

Erschienen in: Current Treatment Options in Psychiatry | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Opinion statement

Prescription opioid misuse has been a significant epidemic during the past decade. Formulations of prescription opioids with different mechanisms of abuse-deterrence have been developed or are currently under development. Given that these medications are substantially more difficult to use in an illicit fashion and minimize the potential for euphoria and/or create an aversive experience when over-ingested, they represent an important next step in pharmacological innovation. Immediate decreases in nonmedical use and in associated overdose mortality and adverse events have been observed after a highly abused opioid, OxyContin, was changed into an abuse-deterrent formulation. However, this reduction in OxyContin use may have simply shifted the drug of choice towards other more easily misused opioids, suggesting that a change in formulation alone will not be sufficient in controlling the epidemic. To control prescription opioid misuse requires treating populations with opioid use disorder and preventing the development of opioid abuse or dependence in unaffected populations. Buprenorphine with naloxone has been designed as an abuse-deterrent formulation, while also demonstrating significant efficacy in treating opioid use disorder. Thus, the dissemination of buprenorphine treatment can be a helpful step in reducing the current epidemic. Other strategies to reduce the epidemic include limiting the availability of leftover prescription opioids through drug take back programs, monitoring physician prescriptions through state prescription monitoring programs, and implementing evidence-based practices in pain management. Increased referral of patients with chronic nonmalignant pain to comprehensive pain rehabilitation programs can also reduce healthcare utilization while improving patient outcomes. Also, routine screening for prescription misuse and referral for addictions treatment must become a standard practice in order to ensure patient safety and create early opportunities for intervention.
Literatur
1.
Zurück zum Zitat Center for Disease Control and Prevetion (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. MMWR. 2011;60:1487–92. Center for Disease Control and Prevetion (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. MMWR. 2011;60:1487–92.
2.
Zurück zum Zitat Center for Disease Control and Prevetion (CDC). Emergency department visits involving nonmedical use of selected prescription drugs—United States, 2004-2008. MMWR. 2010;59:705–9. Center for Disease Control and Prevetion (CDC). Emergency department visits involving nonmedical use of selected prescription drugs—United States, 2004-2008. MMWR. 2010;59:705–9.
4.
Zurück zum Zitat Zosel A, Bartelson BB, Bailey E, Lowenstein S, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS®) System. J Am Acad Child Adolesc Psychiatry. 2013;52:196–204.e2.CrossRefPubMedCentralPubMed Zosel A, Bartelson BB, Bailey E, Lowenstein S, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS®) System. J Am Acad Child Adolesc Psychiatry. 2013;52:196–204.e2.CrossRefPubMedCentralPubMed
5.
Zurück zum Zitat Brandt SA, Taverna EC, Hallock RM. A survey of nonmedical use of tranquilizers, stimulants, and pain relievers among college students: patterns of use among users and factors related to abstinence in non-users. Drug Alcohol Depend. 2014;143:272–6.CrossRefPubMed Brandt SA, Taverna EC, Hallock RM. A survey of nonmedical use of tranquilizers, stimulants, and pain relievers among college students: patterns of use among users and factors related to abstinence in non-users. Drug Alcohol Depend. 2014;143:272–6.CrossRefPubMed
6.
Zurück zum Zitat Schepis TS, Krishnan-Sarin S. Sources of prescriptions for misuse by adolescents: differences in sex, ethnicity, and severity of misuse in a population-based study. J Am Acad Child Adolesc Psychiatry. 2009;48:828–36.CrossRefPubMedCentralPubMed Schepis TS, Krishnan-Sarin S. Sources of prescriptions for misuse by adolescents: differences in sex, ethnicity, and severity of misuse in a population-based study. J Am Acad Child Adolesc Psychiatry. 2009;48:828–36.CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R. Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin. Published online: February 24, 2015. doi:10.1185/03007995.2015.1016607. Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R. Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin. Published online: February 24, 2015. doi:10.​1185/​03007995.​2015.​1016607.
8.
Zurück zum Zitat McCabe SE, West BT, Boyd CJ. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. J Adolesc Health. 2013;52:480–5.CrossRefPubMedCentralPubMed McCabe SE, West BT, Boyd CJ. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. J Adolesc Health. 2013;52:480–5.CrossRefPubMedCentralPubMed
9.•
Zurück zum Zitat Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29. This article compiles data on the abuse risk and routes of administration of 11 commonly prescribed opioid formulations, including hydrocodone, IR and ER oxycodone, methadone, IR and ER morphine, hydromorphone, IR and ER fentanyl, IR and ER oxymorphone. It specifically examined the adjusted risk of each substance based upon their prescription volume. The authors' findings speak to the abuse potential for these compounds in order to facilitate specific approaches to address their abuse.CrossRefPubMedCentralPubMed Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:29. This article compiles data on the abuse risk and routes of administration of 11 commonly prescribed opioid formulations, including hydrocodone, IR and ER oxycodone, methadone, IR and ER morphine, hydromorphone, IR and ER fentanyl, IR and ER oxymorphone. It specifically examined the adjusted risk of each substance based upon their prescription volume. The authors' findings speak to the abuse potential for these compounds in order to facilitate specific approaches to address their abuse.CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17:1142–54.CrossRefPubMed Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17:1142–54.CrossRefPubMed
12.
Zurück zum Zitat Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37:205–17.CrossRefPubMed Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37:205–17.CrossRefPubMed
13.
Zurück zum Zitat Butler SF, Black RA, Serrano JM, Wood ME, Budman SH. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity. J Opioid Manag. 2009;6:239–41.CrossRef Butler SF, Black RA, Serrano JM, Wood ME, Budman SH. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity. J Opioid Manag. 2009;6:239–41.CrossRef
14.
Zurück zum Zitat Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2012;107:587–96.CrossRefPubMedCentralPubMed Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2012;107:587–96.CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Cone EJ, Giordano J, Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend. 2013;131:100–5.CrossRefPubMed Cone EJ, Giordano J, Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend. 2013;131:100–5.CrossRefPubMed
17.
Zurück zum Zitat Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27:808–16.CrossRefPubMed Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27:808–16.CrossRefPubMed
18.
Zurück zum Zitat Perrino PJ, Colucci SV, Apseloff G, Harris SC. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin® tablets compared with original OxyContin® tablets in healthy adults. Clin Drug Investig. 2013;33:441–9.CrossRefPubMedCentralPubMed Perrino PJ, Colucci SV, Apseloff G, Harris SC. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin® tablets compared with original OxyContin® tablets in healthy adults. Clin Drug Investig. 2013;33:441–9.CrossRefPubMedCentralPubMed
19.•
Zurück zum Zitat Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367:187–9. This is an important article that raised the concern of replacement of OxyContin by other opioids and heroin. It also mentions the importance of non-pharmacological strategies for reducing prescription opioid epidemic.CrossRefPubMed Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367:187–9. This is an important article that raised the concern of replacement of OxyContin by other opioids and heroin. It also mentions the importance of non-pharmacological strategies for reducing prescription opioid epidemic.CrossRefPubMed
20.
Zurück zum Zitat Butler SF, Cassidy TA, Chilcoat H, Black RA, Landau C, Budman SH, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14:351–8.CrossRefPubMed Butler SF, Cassidy TA, Chilcoat H, Black RA, Landau C, Budman SH, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14:351–8.CrossRefPubMed
21.
Zurück zum Zitat Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9–17.CrossRefPubMed Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9–17.CrossRefPubMed
22.
Zurück zum Zitat Severtson SG, Bartelson BB, Davis JM, Munoz A, Schneider MF, Chilcoat H, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14:1122–30.CrossRefPubMed Severtson SG, Bartelson BB, Davis JM, Munoz A, Schneider MF, Chilcoat H, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14:1122–30.CrossRefPubMed
23.
Zurück zum Zitat Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22:1274–82.CrossRefPubMedCentralPubMed Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22:1274–82.CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23:1238–46.CrossRefPubMedCentralPubMed Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23:1238–46.CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Bartholomaeus JH, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9:879–91.CrossRefPubMed Bartholomaeus JH, Arkenau-Maric E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9:879–91.CrossRefPubMed
26.
Zurück zum Zitat Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126:206–15.CrossRefPubMedCentralPubMed Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126:206–15.CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Center for Disease Control and Prevetion (CDC). Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012. MMWR. 2013;62:1–4. Center for Disease Control and Prevetion (CDC). Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse--Tennessee, 2012. MMWR. 2013;62:1–4.
28.
Zurück zum Zitat Kapila A, Chhabra L, Chaubey VK, Summers J. Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users. BMJ Case Rep 2014; 2014. Kapila A, Chhabra L, Chaubey VK, Summers J. Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users. BMJ Case Rep 2014; 2014.
29.
Zurück zum Zitat Ambruzs JM, Serrell PB, Rahim N, Larsen CP. Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases. Am J Kidney Dis. 2014;63:1022–6.CrossRefPubMed Ambruzs JM, Serrell PB, Rahim N, Larsen CP. Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases. Am J Kidney Dis. 2014;63:1022–6.CrossRefPubMed
30.
Zurück zum Zitat Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction. 2013;108:1095–106.CrossRefPubMedCentralPubMed Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction. 2013;108:1095–106.CrossRefPubMedCentralPubMed
31.
Zurück zum Zitat Hanna M. Thipphawong J,118 Study Group. A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care. 2008;7:17.CrossRefPubMedCentralPubMed Hanna M. Thipphawong J,118 Study Group. A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care. 2008;7:17.CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat Hanna M, Tuca A, Thipphawong J. An open-label, 1-year extension of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain. BMC Palliat Care. 2009;8:14.CrossRefPubMedCentralPubMed Hanna M, Tuca A, Thipphawong J. An open-label, 1-year extension of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain. BMC Palliat Care. 2009;8:14.CrossRefPubMedCentralPubMed
33.
Zurück zum Zitat Gardner-Nix J, Mercadante S. The role of OROS hydromorphone in the management of cancer pain. Pain Pract. 2010;10:72–7.CrossRefPubMed Gardner-Nix J, Mercadante S. The role of OROS hydromorphone in the management of cancer pain. Pain Pract. 2010;10:72–7.CrossRefPubMed
34.
Zurück zum Zitat Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle Jr RT, Dornseif BE, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002;23:355–68.CrossRefPubMed Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle Jr RT, Dornseif BE, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002;23:355–68.CrossRefPubMed
35.
Zurück zum Zitat Moorman-Li R, Motycka CA, Inge LD, Congdon JM, Hobson S, Pokropski B. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T. 2012;37:412–8.PubMedCentralPubMed Moorman-Li R, Motycka CA, Inge LD, Congdon JM, Hobson S, Pokropski B. A review of abuse-deterrent opioids for chronic nonmalignant pain. P T. 2012;37:412–8.PubMedCentralPubMed
36.
Zurück zum Zitat Raffa RB, Pergolizzi Jr JV. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70:1657–75.CrossRefPubMed Raffa RB, Pergolizzi Jr JV. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70:1657–75.CrossRefPubMed
37.
Zurück zum Zitat Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12:618–31.CrossRefPubMed Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12:618–31.CrossRefPubMed
38.
Zurück zum Zitat Butler SF, Black R, Grimes Serrano JM, Folensbee L, Chang A, Katz N. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med. 2010;11:81–91.CrossRefPubMed Butler SF, Black R, Grimes Serrano JM, Folensbee L, Chang A, Katz N. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation. Pain Med. 2010;11:81–91.CrossRefPubMed
41.
Zurück zum Zitat Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, Webster L. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial. Postgrad Med. 2014;126:20–32.CrossRefPubMed Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, Webster L. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial. Postgrad Med. 2014;126:20–32.CrossRefPubMed
44.
Zurück zum Zitat Darwish M, Yang R, Tracewell W, Robertson Jr P, Bond M. Single- and multiple-dose pharmacokinetics of a hydrochloride bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. Clin Ther. 2014. doi:10.1016/j.clinthera.2014.11.014. Darwish M, Yang R, Tracewell W, Robertson Jr P, Bond M. Single- and multiple-dose pharmacokinetics of a hydrochloride bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers. Clin Ther. 2014. doi:10.​1016/​j.​clinthera.​2014.​11.​014.
45.
Zurück zum Zitat Darwish M, Bond M, Tracewell W, Robertson Jr P, Yang R. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. Clin Drug Investig. 2015;35:13–22.CrossRefPubMed Darwish M, Bond M, Tracewell W, Robertson Jr P, Yang R. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects. Clin Drug Investig. 2015;35:13–22.CrossRefPubMed
46.
Zurück zum Zitat Buer LM, Havens JR, Leukefeld C. Does the new formulation of OxyContin(R) deter misuse? A qualitative analysis. Subst Use Misuse. 2014;49:770–4.CrossRefPubMed Buer LM, Havens JR, Leukefeld C. Does the new formulation of OxyContin(R) deter misuse? A qualitative analysis. Subst Use Misuse. 2014;49:770–4.CrossRefPubMed
47.
Zurück zum Zitat Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014;15:440–51.CrossRefPubMed Cassidy TA, DasMahapatra P, Black RA, Wieman MS, Butler SF. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014;15:440–51.CrossRefPubMed
48.
Zurück zum Zitat Daniels SE, Spivey R, Golf M, Clark FJ, Robson M, Diamond EL, Zimmerman JC, Singla S. Acurox® (Oxycodone HCl/niacin) tablets for the treatment of acute, moderate to severe pain following bunionectomy surgery in adult patients. Poster presented at American Pain Society Annual Meeting. May 7-9, 2009. Available at: http://www.lotuscr.com/lotus-pdf/Acura-Acurox-APS2009-Poster.pdf. Accessed: January 8, 2015. Daniels SE, Spivey R, Golf M, Clark FJ, Robson M, Diamond EL, Zimmerman JC, Singla S. Acurox® (Oxycodone HCl/niacin) tablets for the treatment of acute, moderate to severe pain following bunionectomy surgery in adult patients. Poster presented at American Pain Society Annual Meeting. May 7-9, 2009. Available at: http://​www.​lotuscr.​com/​lotus-pdf/​Acura-Acurox-APS2009-Poster.​pdf. Accessed: January 8, 2015.
50.
Zurück zum Zitat Leibowitz MT, Zamora CA, Brzeczko AW, Stark JG. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with niacin, and oxycodone hydrochloride (Roxicodone) in healthy adults under fasting conditions. Am J Ther. 2014;21:99–105.CrossRefPubMed Leibowitz MT, Zamora CA, Brzeczko AW, Stark JG. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with niacin, and oxycodone hydrochloride (Roxicodone) in healthy adults under fasting conditions. Am J Ther. 2014;21:99–105.CrossRefPubMed
51.
Zurück zum Zitat Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, et al. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (OxectaTM) tablets in nondependent recreational opioid users. J Opioid Manag. 2012;8:315–27.CrossRefPubMed Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, et al. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (OxectaTM) tablets in nondependent recreational opioid users. J Opioid Manag. 2012;8:315–27.CrossRefPubMed
54.
Zurück zum Zitat Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6:300–3.CrossRefPubMed Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6:300–3.CrossRefPubMed
55.
Zurück zum Zitat Setnik B, Roland CL, Goli V, Sommerville K, Webster L. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients. J Opioid Manag. 2013;9:139–50.CrossRefPubMed Setnik B, Roland CL, Goli V, Sommerville K, Webster L. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients. J Opioid Manag. 2013;9:139–50.CrossRefPubMed
56.
Zurück zum Zitat Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R&D. 2011;11:259–75.CrossRef Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R&D. 2011;11:259–75.CrossRef
58.•
Zurück zum Zitat Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. This Cochrane review evaluated 31 randomized controlled trials on the efficacy of buprenorphine in treating opioid addiction, compared to methadone and placebo. It is a thorough review and critical evaluation on this topic.PubMed Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207. This Cochrane review evaluated 31 randomized controlled trials on the efficacy of buprenorphine in treating opioid addiction, compared to methadone and placebo. It is a thorough review and critical evaluation on this topic.PubMed
59.
Zurück zum Zitat Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70:S39–47.CrossRefPubMed Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70:S39–47.CrossRefPubMed
60.
Zurück zum Zitat Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106:1460–73.CrossRefPubMedCentralPubMed Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106:1460–73.CrossRefPubMedCentralPubMed
61.
Zurück zum Zitat Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 1998;50:1–8.CrossRefPubMed Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 1998;50:1–8.CrossRefPubMed
62.
Zurück zum Zitat Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl). 1988;94:484–90.CrossRef Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl). 1988;94:484–90.CrossRef
63.
Zurück zum Zitat Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75–8.CrossRefPubMed Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75–8.CrossRefPubMed
64.
Zurück zum Zitat Furst RT. Suboxone misuse along the opiate maintenance treatment pathway. J Addict Dis. 2013;32:53–67.CrossRefPubMed Furst RT. Suboxone misuse along the opiate maintenance treatment pathway. J Addict Dis. 2013;32:53–67.CrossRefPubMed
65.
Zurück zum Zitat Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003–2005. J Addict Dis. 2007;26:107–11.CrossRefPubMed Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003–2005. J Addict Dis. 2007;26:107–11.CrossRefPubMed
66.
Zurück zum Zitat Soyka M. Buprenorphine and buprenorphine/naloxone intoxication in children—how strong is the risk? Curr Drug Abuse Rev. 2013;6:63–70.CrossRefPubMed Soyka M. Buprenorphine and buprenorphine/naloxone intoxication in children—how strong is the risk? Curr Drug Abuse Rev. 2013;6:63–70.CrossRefPubMed
67.
Zurück zum Zitat Das NG, Das SK. Development of mucoadhesive dosage forms of buprenorphine for sublingual drug delivery. Drug Deliv. 2004;11:89–95.CrossRefPubMed Das NG, Das SK. Development of mucoadhesive dosage forms of buprenorphine for sublingual drug delivery. Drug Deliv. 2004;11:89–95.CrossRefPubMed
68.
Zurück zum Zitat Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble films. Clin Pharmacol Ther. 2011;89:443–9.CrossRefPubMedCentralPubMed Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble films. Clin Pharmacol Ther. 2011;89:443–9.CrossRefPubMedCentralPubMed
69.
Zurück zum Zitat Lintzeris N, Leung SY, Dunlop AJ, Larance B, White N, Rivas GR, et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend. 2013;131:119–26.CrossRefPubMed Lintzeris N, Leung SY, Dunlop AJ, Larance B, White N, Rivas GR, et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend. 2013;131:119–26.CrossRefPubMed
70.
Zurück zum Zitat Sobel BF, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, et al. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend. 2004;73:11–22.CrossRefPubMed Sobel BF, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, et al. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend. 2004;73:11–22.CrossRefPubMed
71.
Zurück zum Zitat Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004;99:1439–49.CrossRefPubMed Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction. 2004;99:1439–49.CrossRefPubMed
72.
Zurück zum Zitat Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K. Selective review and commentary on emerging pharmacotherapies for opioid addiction. Subst Abuse Rehabil. 2011;2:181–8.CrossRefPubMedCentralPubMed Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K. Selective review and commentary on emerging pharmacotherapies for opioid addiction. Subst Abuse Rehabil. 2011;2:181–8.CrossRefPubMedCentralPubMed
73.
Zurück zum Zitat White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend. 2009;103:37–43.CrossRefPubMed White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend. 2009;103:37–43.CrossRefPubMed
75.
Zurück zum Zitat Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108:2141–9.CrossRefPubMed Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction. 2013;108:2141–9.CrossRefPubMed
76.
Zurück zum Zitat Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B. Decline in drug overdose deaths after state policy changes—Florida, 2010-2012. MMWR. 2014;63:569–74.PubMed Johnson H, Paulozzi L, Porucznik C, Mack K, Herter B. Decline in drug overdose deaths after state policy changes—Florida, 2010-2012. MMWR. 2014;63:569–74.PubMed
77.
Zurück zum Zitat Surratt HL, O'Grady C, Kurtz SP, Stivers Y, Cicero TJ, Dart RC, et al. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol Drug Saf. 2014;23:314–20.CrossRefPubMed Surratt HL, O'Grady C, Kurtz SP, Stivers Y, Cicero TJ, Dart RC, et al. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol Drug Saf. 2014;23:314–20.CrossRefPubMed
78.
Zurück zum Zitat Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res. 2006;41:837–55.CrossRefPubMedCentralPubMed Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res. 2006;41:837–55.CrossRefPubMedCentralPubMed
79.
Zurück zum Zitat Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434–42.CrossRefPubMed Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012;13:434–42.CrossRefPubMed
80.
Zurück zum Zitat Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician. 2009;12:507–15.PubMed Wang J, Christo PJ. The influence of prescription monitoring programs on chronic pain management. Pain Physician. 2009;12:507–15.PubMed
81.
Zurück zum Zitat Fischer B, Bibby M, Bouchard M. The global diversion of pharmaceutical drugsnon-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction. 2010;105:2062–70.CrossRefPubMed Fischer B, Bibby M, Bouchard M. The global diversion of pharmaceutical drugsnon-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction. 2010;105:2062–70.CrossRefPubMed
82.
Zurück zum Zitat McCabe SE, West BT, Boyd CJ. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. J Adolesc Health. 2013;52:480–5.CrossRefPubMedCentralPubMed McCabe SE, West BT, Boyd CJ. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. J Adolesc Health. 2013;52:480–5.CrossRefPubMedCentralPubMed
83.
Zurück zum Zitat Tanabe P, Paice JA, Stancati J, Fleming M. How do emergency department patients store and dispose of opioids after discharge? A pilot study. J Emerg Nurs. 2012;38:273–9.CrossRefPubMed Tanabe P, Paice JA, Stancati J, Fleming M. How do emergency department patients store and dispose of opioids after discharge? A pilot study. J Emerg Nurs. 2012;38:273–9.CrossRefPubMed
84.
85.
Zurück zum Zitat Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9:57–60.PubMed Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006;9:57–60.PubMed
86.
Zurück zum Zitat Manchikanti L, Manchukonda R, Pampati V, Damron KS, Brandon DE, Cash KA, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9:123–9.PubMed Manchikanti L, Manchukonda R, Pampati V, Damron KS, Brandon DE, Cash KA, et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006;9:123–9.PubMed
87.
Zurück zum Zitat Bujold E, Huff J, Staton EW, Pace WD. Improving use of narcotics for nonmalignant chronic pain: a lesson from Community Care of North Carolina. J Opioid Manag. 2012;8:363–7.CrossRefPubMed Bujold E, Huff J, Staton EW, Pace WD. Improving use of narcotics for nonmalignant chronic pain: a lesson from Community Care of North Carolina. J Opioid Manag. 2012;8:363–7.CrossRefPubMed
88.
Zurück zum Zitat Gatchel RJ, Okifuji A. Evidence-based scientific data documenting the treatment effectiveness of comprehensive pain programs for chronic nonmalignant pain. J Pain. 2006;7:779–93.CrossRefPubMed Gatchel RJ, Okifuji A. Evidence-based scientific data documenting the treatment effectiveness of comprehensive pain programs for chronic nonmalignant pain. J Pain. 2006;7:779–93.CrossRefPubMed
89.
Zurück zum Zitat Sletten CD, Kurklinsky S, Chinburapa V, Ghazi S. Economic analysis of a comprehensive pain rehabilitation program: a collaboration between Florida Blue and Mayo Clinic Florida. Pain Med. Published online: February 3, 2015. DOI: 10.1111/pme.12679. Sletten CD, Kurklinsky S, Chinburapa V, Ghazi S. Economic analysis of a comprehensive pain rehabilitation program: a collaboration between Florida Blue and Mayo Clinic Florida. Pain Med. Published online: February 3, 2015. DOI: 10.​1111/​pme.​12679.
Metadaten
Titel
Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic
verfasst von
Xiaofan Li, M.D., Ph.D.
Daryl Shorter, M.D.
Thomas Kosten, M.D.
Publikationsdatum
01.06.2015
Verlag
Springer International Publishing
Erschienen in
Current Treatment Options in Psychiatry / Ausgabe 2/2015
Elektronische ISSN: 2196-3061
DOI
https://doi.org/10.1007/s40501-015-0045-6

Weitere Artikel der Ausgabe 2/2015

Current Treatment Options in Psychiatry 2/2015 Zur Ausgabe

Schizophrenia and Other Psychotic Disorders (J Csemansky, Section Editor)

Current Treatments for Delusional Disorder

Schizophrenia and Other Psychotic Disorders (J Csemansky, Section Editor)

Preventing Violence in Patients with Schizophrenia

Schizophrenia and Other Psychotic Disorders (J Csemansky, Section Editor)

Treatment Strategies for Cannabis Use in Schizophrenia

Post-Traumatic Stress Disorders (T Garacioti and K Chard, Section Editors)

Prazosin for the Treatment of PTSD

Substance Use Disorders (FG Moeller, Section Editor)

Outcome Measures in Medication Trials for Substance Use Disorders

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.